移植后的肝门淋巴增殖障碍导致肝动脉狭窄和胆固醇变化
Badi Rawashdeh1, Christina Papageorge2, Yazan Al-Adwan2
1Division of Transplant Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
The American journal of case reports
|January 23, 2025
概括
肝移植后的淋巴增殖性疾病 (PTLD) 可能导致罕见的肝门体质,导致肝动脉狭窄和肝移植后胆道阻塞. 早期考虑PTLD对于诊断和管理至关重要.
科学领域:
- 移植手术 移植手术
- 在瘤学瘤学.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 移植后淋巴增殖障碍 (PTLD) 是器官移植后免疫抑制的罕见并发症.
- PTLD可以表现为超塑性或恶性淋巴细胞增殖,通常与爱斯坦-巴尔病毒 (EBV) 转变有关.
- 它的呈现因局部而异,模仿其他移植后并发症.
研究的目的:
- 报告一个单一的PTLD病例,呈现为肝脏移植的质量效应.
- 突出PTLD作为肝动脉狭窄 (HAS) 和常见的肝管阻塞的原因.
- 强调在早期移植后并发症的差异诊断中考虑PTLD的重要性.
主要方法:
- 一个54岁的女肝移植接受者的病例报告.
- 诊断成像包括磁共振胆血管细胞造影 (MRCP) 和计算机断层扫描 (CT).
- 干预程序:胆道支架和肝动脉支架.
- 组织病理学检查和活检用于诊断.
- 用Rituximab治疗和降低免疫抑制.
主要成果:
- 患者由于肝脏移植质量而出现胆固醇和胆道压缩.
- 质量扩大,导致肝动脉狭窄 (HAS).
- 活检证实了PTLD,Rituximab成功治疗并降低了免疫抑制.
结论:
- PTLD可能不常见地呈现在肝门的质量,导致显著的血管和胆道损害.
- 移植后早期的HAS和胆道阻塞应该促使人们考虑PTLD.
- 及时诊断和多式管理,包括免疫抑制调整和向治疗,是有利结果的关键.
相关概念视频
01:22Portal Hypertension
Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...